ATRA Atara Biotherapeutics Inc.

21.82
0  0%
Previous Close 21.82
Open
Price To Book 3.56
Market Cap 1,010,719,267
Shares 46,320,773
Volume 0
Short Ratio
Av. Daily Volume 709,470

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Initial data due at EAN June 30, 2019, 12:30 CEST.
ATA188
Multiple sclerosis
Phase 3 data due 2020.
ATA 129 (tab-cel) - ALLELE
Epstein-Barr virus (EBV-PTLD) after solid organ transplant (SOT)
Phase 3 data due 2020.
ATA 129 (tab-cel) - MATCH
Epstein-Barr virus (EBV-PTLD) after after hematopoietic cell transplant (HCT)
Phase 1/2 trial ongoing.
ATA129 and KEYTRUDA
Nasopharyngeal carcinoma (NPC)
Phase 2 endpoint not met December 2015
PINTA 745
Protein-energy wasting
Phase 2 presentation at ASH December 2018.
ATA 129
Epstein-Barr virus (EBV-PTLD)
Phase 1 presentation at ASCO June 4, 2019. ORR 63% in patients who also received chemo + pembrolizumab.
Autologous T Cells
Malignant pleural disease

Latest News

  1. Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
  2. Atara Biotherapeutics Announces Collaborator Presentation Updating Positive Phase 1 Clinical Results for a Mesothelin-Targeted CAR T Immunotherapy in Patients with Advanced Mesothelioma
  3. Health Care Digest: Why California biotech thrives, small company looks to crash NASH bash, meeting up at BIO
  4. Atara Biotherapeutics Presents Tab-cel® Clinical Biomarker Results and Nasopharyngeal Carcinoma Study Design at American Society of Clinical Oncology (ASCO) Annual Meeting
  5. Atara Biotherapeutics to Participate at Two Upcoming Investor Conferences
  6. Atara Biotherapeutics Appoints Pascal Touchon President, Chief Executive Officer and Member of the Board of Directors
  7. Edited Transcript of ATRA earnings conference call or presentation 9-May-19 12:30pm GMT
  8. Atara Biotherapeutics Announces Presentations Highlighting Tab-cel® and Mesothelin-Targeted CAR T Clinical Results at American Society of Clinical Oncology (ASCO) Annual Meeting
  9. Atara Biotherapeutics Announces Presentation of Initial ATA188 Phase 1 Safety Results for Patients with Progressive Multiple Sclerosis at the 5th Congress of the European Academy of Neurology (EAN)
  10. Why Atara Biotherapeutics Stock Is Imploding Today
  11. Atara Biotherapeutics: 1Q Earnings Snapshot
  12. Atara Biotherapeutics Announces First Quarter 2019 Financial Results and Recent Operational Progress
  13. Atara Biotherapeutics, Inc. to Host Earnings Call
  14. Atara Biotherapeutics to Announce First Quarter 2019 Financial Results and Host Conference Call on Thursday, May 9, 2019
  15. Where Will Gilead Sciences Spend Its Cash?
  16. Here is What Hedge Funds Think About Atara Biotherapeutics Inc (ATRA)
  17. 2 Best Biotech Buyout Plays
  18. Atara Biotherapeutics Presents Off-the-Shelf, Allogeneic CAR T Preclinical Results at the American Association of Cancer Research (AACR) Annual Meeting 2019